Close
Achema middle east
swop processing & packaging

Bora expands its CDMO capabilities as it makes landmark acquisition of TWi Pharmaceuticals

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

ACHEMA 2027: Global Forum for Pharma and Life Sciences

ACHEMA 2027 sets an even stronger focus on innovations...

Amcor to showcase responsible and patient-centric packaging innovations at CPHI Frankfurt 2025

User-friendly solutions designed to enhance convenience, performance and patient...

Kadans Science Partner secures one of the most significant deals in Glasgow of H1 2025

Chemify scales up operations at Health Innovation Hub Digital...

Fast-growing contract development and manufacturing organization (CDMO), Bora Pharmaceuticals, has completed the acquisition of TWi Pharmaceutical Co.Ltd, a technology-based company specializing in development and commercialization of niche generic drugs.

Acquiring TWi Pharmaceuticals adds two manufacturing facilities and will significantly boost Bora’s service offerings in key areas, such as formulation development, sterile ophthalmic, and niche manufacturing technologies.

Bobby Sheng, CEO of Bora Pharmaceuticals, commented: “The acquisition of TWi Pharmaceuticals marks a huge milestone in Bora’s history as we become the largest pharmaceutical group by volume in Taiwan.

TWi has a long history of strong formulation development, as well as an impeccable quality track record.  As a result of acquiring TWi, Bora will be able to further expand on our capabilities as a full service CDMO. I’m looking forward to continuing our growth in this industry.â€

TWi Pharmaceuticals USA operations will remain a separate entity and be able to take advantage of Bora’s existing large-scale production capacity and transfer the some of the commercial manufacturing of its generic and 505b2 drugs in the United States to the certain Bora sites.

Sheng continued: “This will strengthen Bora’s position as a highly diversified global CDMO. Our expertise and capacity give us an edge over our competitors as we continue to expand our capabilities.â€

Fuelled by the same mission and goal, Bora and TWi will strive to put Taiwan on the map as the centre of global pharmaceutical quality and demonstrate how Bora is an outstanding global supply chain partner.

Bora Pharmaceuticals also recently announced a large acquisition of an early-stage Biologics CDMO and a series of new investments as part of its five-year growth strategy. Bora covers the entire pharmaceutical supply chain from development through to commercial manufacture across a variety of dosage forms.

Latest stories

Related stories

ACHEMA 2027: Global Forum for Pharma and Life Sciences

ACHEMA 2027 sets an even stronger focus on innovations...

Amcor to showcase responsible and patient-centric packaging innovations at CPHI Frankfurt 2025

User-friendly solutions designed to enhance convenience, performance and patient...

Kadans Science Partner secures one of the most significant deals in Glasgow of H1 2025

Chemify scales up operations at Health Innovation Hub Digital...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »